Tiago M. de Carvalho

Tiago M. de Carvalho

Auto-generated profile, based on publicly available information

Tiago M. de Carvalho

Department of Epidemiology and Data Science, Amsterdam UMC VUMC Site, Amsterdam, The Netherlands

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 November 2023 in BMJ Global Health
Verified
Journal Article
Open access
PDF file
TCTiago M de Carvalho
Tiago M de Carvalho
IMIrene Man
Irene Man
DGDamien Georges
Damien Georges
LSLopamudra Ray Saraswati
Lopamudra Ray Saraswati
PBPrince Bhandari
Prince Bhandari
IBIacopo Baussano
Iacopo Baussano
Background Cervical cancer is a major public health problem in India, where access to prevention programmes is low. The WHO-Strategic Advisory Group of Experts recently updated their recommendation for human papillomavirus (HPV) vaccination to include a single-dose option in addition to the two-dose option, which could make HPV vaccination programmes easier to implement and more affordable. Methods We combined projections from a type-specific HPV transmission model and a cancer progression model to assess the health and economic effects of HPV vaccination at national and state level in India. The models used national and state-specific Indian demographic, epidemiological and cost data, and single-dose vaccine efficacy and immunogenicity data from the International Agency for Research on Cancer India vaccine trial with 10-year follow-up. We compared single-dose and two-dose HPV vaccination for a range of plausible scenarios regarding single-dose vaccine protection, coverage and catch-up. We used a healthcare sector payer perspective with a time horizon of 100 years. Results Under the base-case scenario of lifelong protection of single-dose vaccination in 10-year-old girls with 90% coverage, the discounted incremental cost-effectiveness ratio (ICER) of nationwide vaccination relative to no vaccination was US$406 (₹INR30 000) per DALY (disability-adjusted life-years) averted. This lay below an opportunity-cost-based threshold of 30% Indian gross domestic product per capita in each Indian state (state-specific ICER range: US$67–US$593 per DALY averted). The ICER of two-dose vaccination versus no vaccination vaccination was US$1404 (₹INR104 000). The ICER of two-dose vaccination versus single-dose vaccination, assuming lower initial efficacy and waning of single-dose vaccination, was at least US$2282 (₹INR169 000) per DALY averted. Conclusions Nationwide introduction of single-dose HPV vaccination at age 10 in India is highly likely to be cost-effective whereas extending the number of doses from one to two would have a less favourable profile.

8 June 2021 in Medical Decision Making
Verified
Journal Article
Open access
PDF file
TCTiago M. de Carvalho
Tiago M. de Carvalho
JRJoost van Rosmalen
Joost van Rosmalen
HWHenri B. Wolff
Henri B. Wolff
HKHendrik Koffijberg
Hendrik Koffijberg
VCVeerle M. H. Coupé
Veerle M. H. Coupé
Background: Metamodeling may substantially reduce the computational expense of individual-level state transition simulation models (IL-STM) for calibration, uncertainty quantification, and health policy evaluation. However, because of the lack of guidance and readily available computer code, metamodels are still not widely used in health economics and public health. In this study, we provide guidance on how to choose a metamodel for uncertainty quantification. Methods: We built a simulation study to evaluate the prediction accuracy and computational expense of metamodels for uncertainty quantification using life-years gained (LYG) by treatment as the IL-STM outcome. We analyzed how metamodel accuracy changes with the characteristics of the simulation model using a linear model (LM), Gaussian process regression (GP), generalized additive models (GAMs), and artificial neural networks (ANNs). Finally, we tested these metamodels in a case study consisting of a probabilistic analysis of a lung cancer IL-STM. Results: In a scenario with low uncertainty in model parameters (i.e., small confidence interval), sufficient numbers of simulated life histories, and simulation model runs, commonly used metamodels (LM, ANNs, GAMs, and GP) have similar, good accuracy, with errors smaller than 1% for predicting LYG. With a higher level of uncertainty in model parameters, the prediction accuracy of GP and ANN is superior to LM. In the case study, we found that in the worst case, the best metamodel had an error of about 2.1%. Conclusion: To obtain good prediction accuracy, in an efficient way, we recommend starting with LM, and if the resulting accuracy is insufficient, we recommend trying ANNs and eventually also GP regression.

15 April 2023 in medRxiv
Verified
Preprint
Open access
PDF file
TCTm de Carvalho
Tm de Carvalho
IMI Man
I Man
DGD Georges
D Georges
LSLr Saraswati
Lr Saraswati
PBP Bhandari
P Bhandari
IBI Baussano
I Baussano
Background Cervical cancer is a major public health problem in India, where access to prevention programmes is low. The World Health Organization-Strategic Advisory Group of Experts recently updated their recommendation for human papillomavirus (HPV) vaccination to include a single-dose option in addition to the two-dose option, which could make HPV vaccination programmes easier to implement and more affordable. Methods We combined projections from a type-specific HPV transmission model and a cancer progression model to assess the health and economic effects of HPV vaccination at national and state-level in India. The models used national and state-specific Indian demographic, epidemiological and cost data, and single-dose vaccine efficacy and immunogenicity data from the IARC India vaccine trial with 10-year follow-up. We compared single- and two-dose HPV vaccination for a range of plausible scenarios regarding single-dose vaccine protection, coverage and catch-up. Results Under the base-case scenario of life-long protection of single-dose vaccination in 10-year-old girls with 90% coverage, the incremental cost-effectiveness ratio (ICER) of nationwide vaccination relative to no vaccination was $405 per DALY averted and lay below an opportunity-cost based threshold of 30% Indian GDP per capita in each state (state-specific ICER range: $67 to $593 per DALY averted). The ICER of two-dose vaccination versus no vaccination and versus single-dose vaccination was $1403 and minimum $2279 per DALY averted, respectively. Conclusions Nationwide introduction of single-dose HPV vaccination in India is highly likely to be cost-effective whereas extending the number of doses from one to two would have a less favourable profile. Funding Bill & Melinda Gates Foundation. What is already known in this topic In 2020, the World Health Organization (WHO) launched a global call for elimination of cervical cancer as a public health problem, of which HPV vaccination is a key pillar. However, access to HPV vaccination in India is still very low. In April 2022, the WHO Strategic Advisory Group of Experts (SAGE) issued a recommendation for countries to update their dosing schedules to include a single-dose option. Single-dose HPV vaccination is likely to be more affordable and would greatly facilitate the implementation of HPV vaccination. The key questions for India are whether, with a realistic cost-effectiveness threshold (30% GDP per capita), single-dose HPV vaccination would be a cost-effective intervention; and whether two-dose vaccination could still be affordable and worthwhile compared to a single-dose schedule, given the uncertainty in its initial efficacy and long-term protection. What this study adds We used state-specific cancer incidence and locally collected cost data and built plausible vaccination efficacy scenarios based on the IARC India trial to inform the cost-effectiveness estimates. Single-dose vaccination in India would be cost-effective under a cost-effectiveness threshold of 30% of the Indian GDP per capita and the annual budget impact would be less than 10% of the cost of the current Indian universal childhood vaccination programme. Even though there was substantial heterogeneity, we confirmed that single-dose vaccination would be cost-effective across all Indian states. Catch-up single-dose vaccination to age 15 or 20 is a cost-effective strategy. However, the decision to implement catch-up will depend on the willingness of the health authorities to support a higher initial investment. We found two-dose vaccination to have a less favourable cost-effectiveness profile. How this study might affect research practice and policy Single-dose vaccination achieved a better balance between health benefits and financial burden than two-dose vaccination, even after taking into account uncertainty in the level of protection provided by single-dose HPV vaccination. Our results could be used by Indian health authorities at the national and state-level to inform their decision and planning of the implementation of HPV vaccination in India and could convey several lessons for other low and middle income countries.